CH653021A5
(fr)
|
1981-04-24 |
1985-12-13 |
Delalande Sa |
Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
WO1990014844A2
(en)
|
1989-06-06 |
1990-12-13 |
Neorx Corporation |
Sugars as cleavable linkers for the delivery and release of agents in native form
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
US6069149A
(en)
|
1997-01-09 |
2000-05-30 |
Terumo Kabushiki Kaisha |
Amide derivatives and intermediates for the synthesis thereof
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US20090208418A1
(en)
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
US20020155108A1
(en)
|
1998-05-04 |
2002-10-24 |
Biocrystal, Ltd. |
Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
|
FI107193B
(fi)
|
1999-06-03 |
2001-06-15 |
Rouvari Oy R |
Mittausanturi
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
EP1272526A4
(en)
|
2000-04-13 |
2004-10-13 |
Univ Rockefeller |
REINFORCING ANTIBODY-IMMUNE RESPONSE
|
AU2001270134B2
(en)
|
2000-06-22 |
2006-06-15 |
University Of Iowa Research Foundation |
Methods for enhancing antibody-induced cell lysis and treating cancer
|
MXPA03003632A
(es)
|
2000-10-24 |
2003-09-10 |
Immunex Corp |
Metodo para tratamiento de tumores usando terapia de combinacion.
|
JP2005500510A
(ja)
|
2000-12-08 |
2005-01-06 |
スリーエム イノベイティブ プロパティズ カンパニー |
インターフェロンαを選択的に誘導する化合物を同定するための選別法
|
US20060142202A1
(en)
|
2000-12-08 |
2006-06-29 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
AU2002343728A1
(en)
|
2001-11-16 |
2003-06-10 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor pathways
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
ATE417067T1
(de)
|
2002-03-01 |
2008-12-15 |
Immunomedics Inc |
Rs7 antikörper
|
JP4860923B2
(ja)
|
2002-08-15 |
2012-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性組成物、および免疫応答の刺激方法
|
US6924154B2
(en)
|
2002-08-20 |
2005-08-02 |
Quest Diagnostics Investments Incorporated |
Hydrophilic chemilumescent acridinium labeling reagents
|
EP1542688A4
(en)
|
2002-09-26 |
2010-06-02 |
3M Innovative Properties Co |
1H-imidazo dimers
|
AU2003287324A1
(en)
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
AU2003287316A1
(en)
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
US7091214B2
(en)
|
2002-12-20 |
2006-08-15 |
3M Innovative Properties Co. |
Aryl substituted Imidazoquinolines
|
EP2572715A1
(en)
|
2002-12-30 |
2013-03-27 |
3M Innovative Properties Company |
Immunostimulatory Combinations
|
US7375180B2
(en)
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
US7485432B2
(en)
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
WO2004087049A2
(en)
|
2003-03-25 |
2004-10-14 |
3M Innovative Properties Company |
Selective activation of cellular activities mediated through a common toll-like receptor
|
JP2007514644A
(ja)
|
2003-04-10 |
2007-06-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応を向上させる方法および組成物
|
WO2004091500A2
(en)
|
2003-04-10 |
2004-10-28 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
US20040214851A1
(en)
|
2003-04-28 |
2004-10-28 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
MY157827A
(en)
|
2003-06-27 |
2016-07-29 |
3M Innovative Properties Co |
Sulfonamide substituted imidazoquinolines
|
WO2005016275A2
(en)
|
2003-08-05 |
2005-02-24 |
3M Innovative Properties Company |
Formulations containing an immune response modifier
|
AU2004266657B2
(en)
|
2003-08-14 |
2009-07-02 |
3M Innovative Properties Company |
Lipid-modified immune response modifiers
|
US8198020B2
(en)
|
2003-08-22 |
2012-06-12 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
MXPA06002199A
(es)
|
2003-08-27 |
2006-05-22 |
3M Innovative Properties Co |
Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
WO2005051324A2
(en)
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20050158325A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Immunomodulatory combinations
|
US20060018911A1
(en)
|
2004-01-12 |
2006-01-26 |
Dana Ault-Riche |
Design of therapeutics and therapeutics
|
AU2005228150A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
JP2007532572A
(ja)
|
2004-04-09 |
2007-11-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調整剤を送達させるための方法、組成物および調製物
|
CA2565827A1
(en)
|
2004-05-05 |
2005-12-15 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006028545A2
(en)
|
2004-06-18 |
2006-03-16 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20060135459A1
(en)
|
2004-11-09 |
2006-06-22 |
Epstein Alan L |
Targeted innate immunity
|
EP1814908A4
(en)
|
2004-11-22 |
2009-07-01 |
Biosight Ltd |
Activated labeling reagents and method for their preparation and use
|
WO2006074003A2
(en)
|
2004-12-30 |
2006-07-13 |
3M Innovative Properties Company |
CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
|
EP1835935A4
(en)
|
2004-12-30 |
2009-06-17 |
Univ Rockefeller |
COMPOSITIONS AND METHODS FOR IMPROVED DENDRITIC CELL REPRODUCTION AND FUNCTION
|
AU2006210392A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune response modifiers
|
US8658666B2
(en)
|
2005-02-11 |
2014-02-25 |
3M Innovative Properties Company |
Substituted imidazoquinolines and imidazonaphthyridines
|
WO2007014327A2
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
EP1931352B1
(en)
|
2005-08-22 |
2016-04-13 |
The Regents of The University of California |
Tlr agonists
|
US7700321B2
(en)
|
2005-10-21 |
2010-04-20 |
Genzyme Corporation |
Antibody-based therapeutics with enhanced ADCC activity
|
US20080286819A1
(en)
|
2005-11-07 |
2008-11-20 |
Ravetch Jeffrey V |
Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
|
EP3085373A1
(en)
|
2006-02-22 |
2016-10-26 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
CA2652599C
(en)
|
2006-05-03 |
2019-09-24 |
Ross Kedl |
Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
|
EP2630968A1
(en)
|
2006-06-30 |
2013-08-28 |
Baylor Research Institute |
Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
GB0614098D0
(en)
|
2006-07-15 |
2006-08-23 |
Mnl Pharma Ltd |
Immune response variegation with imino sugars
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
US20080241139A1
(en)
|
2006-10-31 |
2008-10-02 |
Regents Of The University Of Colorado |
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
CN102586186A
(zh)
|
2007-02-23 |
2012-07-18 |
贝勒研究院 |
通过clec-6激活人抗原呈递细胞
|
TWI423985B
(zh)
|
2007-02-23 |
2014-01-21 |
Baylor Res Inst |
利用dectin-1活化人類抗原呈現細胞之醫療應用
|
NZ597466A
(en)
|
2007-03-01 |
2013-08-30 |
Symphogen As |
Recombinant anti-epidermal growth factor receptor antibody compositions
|
US8604172B2
(en)
|
2009-04-17 |
2013-12-10 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
US20110182847A1
(en)
|
2007-06-15 |
2011-07-28 |
Randolph Noelle |
Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens
|
MX2010001194A
(es)
|
2007-07-31 |
2010-07-30 |
Univ Louisiana State |
Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
|
WO2009059309A2
(en)
|
2007-11-01 |
2009-05-07 |
Panacea Pharmaceuticals, Inc. |
Furin-cleavable peptide linkers for drug-ligand conjugates
|
US20100098657A1
(en)
|
2007-12-27 |
2010-04-22 |
Schafer Peter H |
Method of Treating Cancer with Immunomodulatory Compounds and IgG
|
WO2009093250A2
(en)
|
2008-01-25 |
2009-07-30 |
Gavish-Galilee Bio Applications Ltd |
Targeting of innate immune response to tumor site
|
BRPI0906309A2
(pt)
|
2008-04-02 |
2020-05-26 |
Macrogenics, Inc |
Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
|
SI2281006T1
(sl)
|
2008-04-30 |
2017-12-29 |
Immunogen, Inc. |
Premreževalci in njihova uporaba
|
JP2010032505A
(ja)
|
2008-06-30 |
2010-02-12 |
Arkray Inc |
目的物質の検出方法、それに用いる検出試薬およびその用途
|
MX341883B
(es)
|
2008-08-05 |
2016-09-07 |
Toray Industries |
Composicion farmaceutica para el tratamiento y prevencion de canceres.
|
US20100129383A1
(en)
|
2008-10-03 |
2010-05-27 |
The Governors Of The University Of Alberta |
Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
BR112012003703A2
(pt)
|
2009-08-18 |
2020-12-08 |
Ventrix Phramaceuticals, INC. |
Benzoazepinas substituídas como moduladores do receptor tipo toll
|
DK2467377T3
(en)
|
2009-08-18 |
2017-04-03 |
Ventirx Pharmaceuticals Inc |
SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
|
JP2013504585A
(ja)
|
2009-09-09 |
2013-02-07 |
セントローズ, エルエルシー |
細胞外標的化薬物複合体
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
GB0917054D0
(en)
|
2009-09-29 |
2009-11-11 |
Cytoguide As |
Agents, uses and methods
|
GB0917044D0
(en)
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
PT2532366T
(pt)
|
2010-02-04 |
2016-12-20 |
Toray Industries |
Composição farmacêutica para o tratamento e/ou prevenção de cancro
|
BR112012018949A2
(pt)
|
2010-02-04 |
2020-09-01 |
Toray Industries |
Composições farmacêuticas, anticorpos, combinação farmacêutica, métodos para o tratamento e/ou prevenção de um câncer, usos de uma composição farmacêutica, uso5 de um anticorpo e uso de uma combinação farmacêutica
|
RU2607366C2
(ru)
|
2010-02-04 |
2017-01-10 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
US8911740B2
(en)
|
2010-02-04 |
2014-12-16 |
Toray Industries, Inc. |
Pharmaceutical composition for treating and/or preventing cancer
|
PT2532680E
(pt)
|
2010-02-04 |
2015-09-14 |
Toray Industries |
Composição medicinal para tratar e/ou prevenir o cancro
|
US9203872B2
(en)
|
2010-02-19 |
2015-12-01 |
Microsoft Technology Licensing, Llc |
Distributed connectivity policy enforcement with ICE
|
GB201003293D0
(en)
|
2010-02-26 |
2010-04-14 |
Adjuvantix Ltd |
Cancer vaccine
|
JP6066732B2
(ja)
|
2010-03-05 |
2017-01-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的免疫調節抗体および融合タンパク質に基づく組成物および方法
|
KR101958753B1
(ko)
|
2010-04-13 |
2019-03-15 |
셀덱스 쎄라퓨틱스, 인크. |
인간 cd27에 결합하는 항체 및 이의 용도
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
KR20130036246A
(ko)
|
2010-05-07 |
2013-04-11 |
베일러 리서치 인스티튜트 |
사람 cd8+ t 세포의 수지상 세포 면역수용체(dcir)-매개 교차프라이밍
|
PL2571532T3
(pl)
|
2010-05-14 |
2017-10-31 |
Abbvie Inc |
Białka wiążące IL-1
|
EP2594589A1
(en)
|
2010-06-10 |
2013-05-22 |
Sapporo Medical University |
ANTI-Trop-2 ANTIBODY
|
AU2011274423B2
(en)
|
2010-07-09 |
2016-02-11 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
JP5913307B2
(ja)
|
2010-07-12 |
2016-04-27 |
コヴェックス・テクノロジーズ・アイルランド・リミテッド |
多機能性抗体複合体
|
MX2013001527A
(es)
|
2010-08-13 |
2013-04-24 |
Baylor Res Inst |
Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos.
|
SG189071A1
(en)
|
2010-10-01 |
2013-05-31 |
Ventirx Pharmaceuticals Inc |
Therapeutic use of a tlr agonist and combination therapy
|
US20120328605A1
(en)
|
2010-10-27 |
2012-12-27 |
Daniel Larocque |
Compositions and uses
|
JP6014596B2
(ja)
|
2010-11-09 |
2016-10-25 |
メディミューン,エルエルシー |
均一コンジュゲーションのための抗体足場
|
WO2012092552A1
(en)
|
2010-12-30 |
2012-07-05 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers with reactive groups that release biologically active agents
|
US20120231023A1
(en)
|
2011-03-08 |
2012-09-13 |
Baylor Research Institute |
Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells
|
CA2831294A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン,エルエルシー |
B7−h1およびpd−1に結合する抗体およびその他の分子
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
WO2012166555A1
(en)
|
2011-05-27 |
2012-12-06 |
Nektar Therapeutics |
Water - soluble polymer - linked binding moiety and drug compounds
|
JP6460789B2
(ja)
|
2011-06-03 |
2019-01-30 |
スリーエム イノベイティブ プロパティズ カンパニー |
ポリエチレングリコールセグメントを有するヘテロ2官能性リンカー及び該リンカーから調製された免疫反応調節複合体
|
CN103582640B
(zh)
|
2011-06-03 |
2015-11-25 |
3M创新有限公司 |
肼基1h-咪唑并喹啉-4-胺以及由其制成的缀合物
|
WO2012170072A1
(en)
|
2011-06-06 |
2012-12-13 |
Immungene, Inc. |
Engineered antibody-tnfsf member ligand fusion molecules
|
AU2012290949B2
(en)
|
2011-08-04 |
2017-03-02 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
|
DK2740795T3
(en)
|
2011-08-04 |
2017-01-16 |
Toray Industries |
Pharmaceutical composition for the treatment and / or prevention of cancer
|
AU2012290955B2
(en)
|
2011-08-04 |
2017-04-27 |
Toray Industries, Inc. |
Drug composition for cancer treatment and/or prevention
|
PL2740796T3
(pl)
|
2011-08-04 |
2017-10-31 |
Toray Industries |
Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi
|
MX349907B
(es)
|
2011-08-04 |
2017-08-18 |
Toray Industries |
Metodo para detectar cancer pancreatico.
|
AU2012290946B2
(en)
|
2011-08-04 |
2016-04-21 |
Toray Industries, Inc. |
Cancer treatment and/or prevention drug composition
|
US9175074B2
(en)
|
2011-08-04 |
2015-11-03 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prophylaxis of cancer
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン,エルエルシー |
抗b7−h4抗体およびその使用
|
MX2014002363A
(es)
|
2011-09-01 |
2014-04-14 |
Novartis Ag |
Formulaciones de antigenos de staphylococcus aureus con adyuvante.
|
JP2014527983A
(ja)
|
2011-09-19 |
2014-10-23 |
ザ ジョンズ ホプキンス ユニバーシティー |
癌免疫療法
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
EP2776070A4
(en)
|
2011-11-09 |
2016-02-10 |
Ascend Biopharmaceuticals Ltd |
IMMUNOMODULATORY CONJUGATES
|
CN104053672A
(zh)
|
2011-11-11 |
2014-09-17 |
瑞纳神经科学公司 |
Trop-2特异性抗体及其用途
|
EP3539982A3
(en)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
EP3447071A1
(en)
|
2012-01-09 |
2019-02-27 |
Pfizer Healthcare Ireland |
Mutant antibodies and conjugation thereof
|
JP6247226B2
(ja)
|
2012-01-10 |
2017-12-13 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
血液脳関門を越える治療分子の輸送の向上
|
KR20140126357A
(ko)
|
2012-02-01 |
2014-10-30 |
컴퓨젠 엘티디. |
C1orf32 항체 및 이의 암 치료를 위한 용도
|
IN2014KN01716A
(ja)
|
2012-02-21 |
2015-10-23 |
Toray Industries |
|
EP2818482B1
(en)
|
2012-02-21 |
2019-05-22 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment of cancer
|
PT2818483T
(pt)
|
2012-02-21 |
2017-10-09 |
Toray Industries |
Composição medicinal para tratamento e/ou prevenção de cancro
|
EP2818481B1
(en)
|
2012-02-21 |
2019-08-07 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
EP2819788B1
(en)
|
2012-02-27 |
2018-08-22 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
PL2832365T3
(pl)
|
2012-03-30 |
2018-04-30 |
Toray Industries, Inc. |
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
|
CN104203281B
(zh)
|
2012-03-30 |
2019-07-26 |
东丽株式会社 |
胆囊癌的治疗和/或预防用药物组合物
|
WO2013155526A2
(en)
|
2012-04-13 |
2013-10-17 |
Whitehead Institute For Biomedical Research |
Sortase- modified vhh domains and uses thereof
|
US9556167B2
(en)
|
2012-05-02 |
2017-01-31 |
Yale University |
TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
|
CN104640933A
(zh)
|
2012-05-30 |
2015-05-20 |
生命科技公司 |
荧光pH敏感性染料和其使用方法
|
EP2674170B1
(en)
|
2012-06-15 |
2014-11-19 |
Invivogen |
Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
US20140065096A1
(en)
|
2012-09-05 |
2014-03-06 |
Regen BioPharma, Inc. |
Cancer therapy by ex vivo activated autologous immune cells
|
WO2014124316A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
WO2014177042A1
(zh)
|
2013-04-28 |
2014-11-06 |
Qin Gang |
一种新型的连接子及其制备方法和用途
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
HUE042081T2
(hu)
|
2013-08-09 |
2019-06-28 |
Toray Industries |
Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
|
SG11201604879QA
(en)
|
2013-10-15 |
2016-07-28 |
Sorrento Therapeutics Inc |
Drug-conjugates with a targeting molecule and two different drugs
|
GB201321242D0
(en)
|
2013-12-02 |
2014-01-15 |
Immune Targeting Systems Its Ltd |
Immunogenic compound
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
HUE047699T2
(hu)
|
2013-12-17 |
2020-05-28 |
Hoffmann La Roche |
Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával
|
SG10201902571VA
(en)
|
2013-12-25 |
2019-04-29 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antibody-drug conjugate
|
SG11201605296SA
(en)
|
2014-01-10 |
2016-07-28 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for treating her2 positive tumors
|
WO2015112749A2
(en)
|
2014-01-22 |
2015-07-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
EP3909603A1
(en)
|
2014-02-21 |
2021-11-17 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Glycotargeting therapeutics
|
EP3129407A2
(en)
|
2014-03-12 |
2017-02-15 |
Novartis Ag |
Specific sites for modifying antibodies to make immunoconjugates
|
EP4015535A1
(en)
|
2014-03-19 |
2022-06-22 |
Genzyme Corporation |
Site-specific glycoengineering of targeting moieties
|
RU2711485C2
(ru)
|
2014-04-11 |
2020-01-17 |
МЕДИММЬЮН, ЭлЭлСи |
Конъюгированные соединения, содержащие сконструированные с цистеином антитела
|
EP3134402B1
(en)
|
2014-04-22 |
2020-05-06 |
F.Hoffmann-La Roche Ag |
4-amino-imidazoquinoline compounds
|
EP3517114A1
(en)
|
2014-04-29 |
2019-07-31 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
New stable antibody-drug conjugate, preparation method and use thereof
|
US20170073415A1
(en)
|
2014-05-12 |
2017-03-16 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
EP3145552B1
(en)
|
2014-05-23 |
2020-03-04 |
Novartis AG |
Methods for making conjugates from disulfide-containing proteins
|
CA2950293A1
(en)
|
2014-06-02 |
2015-12-10 |
Baylor Research Institute |
Methods and compositions for treating allergy and inflammatory diseases
|
WO2015187835A2
(en)
|
2014-06-06 |
2015-12-10 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
EP3166976B1
(en)
|
2014-07-09 |
2022-02-23 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1 combinations for treating tumors
|
US20160015803A1
(en)
|
2014-07-18 |
2016-01-21 |
Ross Kedl |
Immunostimulatory combinations and use thereof
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
WO2016028149A1
(en)
|
2014-08-20 |
2016-02-25 |
Tu Eindhoven |
Ureidopyrimidone supramolecular complexes for compound delivery into cells
|
WO2016032009A1
(en)
|
2014-08-27 |
2016-03-03 |
Kyushu University, National University Corporation |
Adjuvant
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
US9884866B2
(en)
|
2014-09-08 |
2018-02-06 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US20170304433A1
(en)
|
2014-10-09 |
2017-10-26 |
Wake Forest University Health Sciences |
Vaccine compositions and methods of use to treat neonatal subjects
|
GB201418004D0
(en)
|
2014-10-10 |
2014-11-26 |
Isis Innovation |
Polymer adjuvant
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
EP3209334A2
(en)
|
2014-10-20 |
2017-08-30 |
Igenica Biotherapeutics, Inc. |
Novel antibody-drug conjugates and related compounds, compositions, and methods of use
|
WO2016064899A1
(en)
|
2014-10-21 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
WO2016081748A2
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies against cd73 and uses thereof
|
WO2016085967A1
(en)
|
2014-11-25 |
2016-06-02 |
Endocyte, Inc. |
Methods of treating cancer by targeting tumor-associated macrophages
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
WO2016109310A1
(en)
|
2014-12-31 |
2016-07-07 |
Checkmate Pharmaceuticals, Llc |
Combination tumor immunotherapy
|
PE20171185A1
(es)
|
2015-01-14 |
2017-08-22 |
Bristol Myers Squibb Co |
Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso
|
TWI702234B
(zh)
|
2015-01-16 |
2020-08-21 |
中央研究院 |
中心核構建體及其於組設藥物分子的用途
|
ES2761861T3
(es)
|
2015-01-21 |
2020-05-21 |
Univ Leland Stanford Junior |
Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
WO2016141890A1
(en)
|
2015-03-12 |
2016-09-15 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as hepatitis c virus inhibitors and pharmaceutical uses thereof
|
EP3268392A2
(en)
|
2015-03-13 |
2018-01-17 |
CytomX Therapeutics, Inc. |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
KR20170128567A
(ko)
|
2015-03-23 |
2017-11-22 |
바이엘 파마 악티엔게젤샤프트 |
항-ceacam6 항체 및 그의 용도
|
WO2016161372A1
(en)
|
2015-04-01 |
2016-10-06 |
President And Fellows Of Harvard College |
Immunoconjugates for programming or reprogramming of cells
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
US10745481B2
(en)
|
2015-05-04 |
2020-08-18 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
CN108026170B
(zh)
|
2015-05-04 |
2022-03-01 |
西托姆克斯治疗公司 |
抗cd71抗体、可活化抗cd71抗体及其使用方法
|
US20160324981A1
(en)
|
2015-05-08 |
2016-11-10 |
The California Institute For Biomedical Research |
Liver x receptor agonists and uses thereof
|
WO2016187122A1
(en)
|
2015-05-15 |
2016-11-24 |
University Of Iowa Research Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
JP6602958B2
(ja)
|
2015-05-20 |
2019-11-06 |
イミュンワーク インク. |
標的化成分及びエフェクター成分を有する分子構築物、並びにそれらの使用
|
CN107849614A
(zh)
|
2015-05-22 |
2018-03-27 |
拉筹伯大学 |
诊断乳腺癌的方法
|
PL3303396T3
(pl)
|
2015-05-29 |
2023-03-06 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko ox40 i ich zastosowanie
|
ES2789500T5
(es)
|
2015-05-29 |
2023-09-20 |
Hoffmann La Roche |
Procedimientos terapéuticos y de diagnóstico para el cáncer
|
EP3302457A2
(en)
|
2015-06-08 |
2018-04-11 |
Lophius Biosciences GmbH |
Composition for determination of cell-mediated immune responsiveness
|
CN112125929A
(zh)
|
2015-06-15 |
2020-12-25 |
杭州多禧生物科技有限公司 |
用于偶联的亲水链接体
|
WO2016205566A1
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
WO2016205551A2
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
WO2016203025A1
(en)
|
2015-06-17 |
2016-12-22 |
Curevac Ag |
Vaccine composition
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
WO2015151080A2
(en)
|
2015-07-04 |
2015-10-08 |
Suzhou M-Conj Biotech Co., Ltd |
Specific conjugation of a cell-binding molecule
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
MX2018000621A
(es)
|
2015-07-13 |
2018-05-11 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
CN108025051B
(zh)
|
2015-07-29 |
2021-12-24 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
AU2016303497A1
(en)
|
2015-07-31 |
2018-03-01 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
AU2016304597B2
(en)
|
2015-08-06 |
2022-10-06 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for tumor therapy
|
WO2015155753A2
(en)
|
2015-08-10 |
2015-10-15 |
Suzhou M-Conj Biotech Co., Ltd |
Novel linkers and their uses in specific conjugation of drugs to a biological molecule
|
KR102685007B1
(ko)
|
2015-08-31 |
2024-07-12 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
구아니딘 치환된 이미다조[4,5-c] 고리 화합물
|
US10118925B2
(en)
|
2015-08-31 |
2018-11-06 |
3M Innovative Properties Company |
Imidazo[4,5-c] ring compounds containing substituted guanidine groups
|
CN108431045B
(zh)
|
2015-09-01 |
2022-05-13 |
免疫功坊股份有限公司 |
用以预防血栓形成及/或治疗血栓的分子构建体
|
WO2017044803A1
(en)
|
2015-09-09 |
2017-03-16 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Service |
Expression vector delivery system and use thereof for inducing an immune response
|
EP3350178B1
(en)
|
2015-09-14 |
2021-10-20 |
Pfizer Inc. |
Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
|
WO2017053720A1
(en)
|
2015-09-25 |
2017-03-30 |
Tarveda Therapeutics, Inc. |
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
|
WO2017058996A1
(en)
|
2015-09-29 |
2017-04-06 |
The University Of Chicago |
Polymer conjugate vaccines
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
CN108367011A
(zh)
|
2015-11-02 |
2018-08-03 |
文蒂雷克斯药品公司 |
使用tlr8激动剂治疗癌症
|
EP3374399A1
(en)
|
2015-11-11 |
2018-09-19 |
Opi Vi- IP Holdco LLC |
Composition and methods for anti-tnfr2 antibodies
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
TWI812873B
(zh)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
DE212016000029U1
(de)
|
2015-12-07 |
2017-07-30 |
Opi Vi - Ip Holdco Llc |
Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
WO2017117269A1
(en)
|
2015-12-29 |
2017-07-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for dectin-2 stimulation and cancer immunotherapy
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
CA3209672A1
(en)
|
2016-02-04 |
2016-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
WO2017180834A1
(en)
|
2016-04-13 |
2017-10-19 |
Tarveda Therapeutics, Inc. |
Neurotensin receptor binding conjugates and formulations thereof
|
CN109071665B
(zh)
|
2016-04-18 |
2022-11-01 |
塞德斯医疗公司 |
结合人cd40的激动性抗体及其用途
|
WO2017184735A1
(en)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
AU2017252640A1
(en)
|
2016-04-19 |
2018-12-06 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
EP3455257B1
(en)
|
2016-05-09 |
2021-09-22 |
IGM Biosciences Inc. |
Anti-pd-l1 antibodies
|
TW201801751A
(zh)
|
2016-05-13 |
2018-01-16 |
塔維達治療公司 |
靶向構建體及其製劑
|
WO2017210246A2
(en)
|
2016-05-31 |
2017-12-07 |
Tarveda Therapeutics, Inc. |
Penicillamine conjugates and particles and formulations thereof
|
CA3028721A1
(en)
|
2016-06-20 |
2017-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
WO2018009672A1
(en)
|
2016-07-06 |
2018-01-11 |
University Of Maryland, College Park |
Polyphosphazene polyelectrolytes and uses thereof
|
EP3484518A4
(en)
*
|
2016-07-07 |
2020-04-22 |
The Board of Trustees of the Leland Stanford Junior University |
ANTIBODY ADJUVANT CONJUGATES
|
EP3922279A1
(en)
|
2016-08-30 |
2021-12-15 |
Dana Farber Cancer Institute, Inc. |
Drug delivery compositions and uses thereof
|
WO2018045150A1
(en)
|
2016-09-02 |
2018-03-08 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
US11274115B2
(en)
|
2016-09-07 |
2022-03-15 |
Glaxosmithkline Biological Sa |
Imidazoquinoline derivatives and their use in therapy
|
US10954233B2
(en)
|
2016-09-09 |
2021-03-23 |
Novartis Ag |
Compounds and compositions as inhibitors of endosomal toll-like receptors
|
JP7265989B2
(ja)
|
2016-10-25 |
2023-04-27 |
ウロゲン ファーマ リミテッド |
体腔の免疫調節治療
|
CA3041979A1
(en)
|
2016-10-28 |
2018-05-03 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
CN116143678A
(zh)
|
2016-11-14 |
2023-05-23 |
杭州多禧生物科技有限公司 |
偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
CA3046790A1
(en)
|
2016-12-13 |
2018-06-21 |
Bolt Biotherapeutics, Inc. |
Antibody adjuvant conjugates
|
EP3559045A4
(en)
|
2016-12-23 |
2020-08-19 |
REMD Biotherapeutics, Inc. |
IMMUNOTHERAPY USING ANTIBODIES THAT BIND TO A TIMED DEATH LIGAND 1 (PD-L1)
|
WO2018119474A2
(en)
|
2016-12-23 |
2018-06-28 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind programmed death 1 (pd-1)
|
CA3049254A1
(en)
|
2017-01-10 |
2018-07-19 |
Nektar Therapeutics |
Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods
|
WO2018140831A2
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
WO2018144955A1
(en)
|
2017-02-02 |
2018-08-09 |
Silverback Therapeutics, Inc. |
Construct-peptide compositions and methods of use thereof
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
US20190374650A1
(en)
|
2017-02-22 |
2019-12-12 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of polymer/biomacromolecule conjugates
|
US20200016267A1
(en)
|
2017-03-06 |
2020-01-16 |
Merck Patent Gmbh |
Aqueous anti-pd-l1 antibody formulation
|
ES2894731T3
(es)
|
2017-03-15 |
2022-02-15 |
Silverback Therapeutics Inc |
Compuestos de benzazepina, conjugados y usos de los mismos
|
CN110430897B
(zh)
|
2017-03-16 |
2021-01-22 |
免疫功坊股份有限公司 |
接合单元及包含接合单元的分子构建体
|
WO2018175854A1
(en)
|
2017-03-23 |
2018-09-27 |
The Children's Medical Center Corporation |
Methods and compositions relating to adjuvants
|
KR20190135007A
(ko)
|
2017-03-31 |
2019-12-05 |
자임워크스 인코포레이티드 |
종양 항원 제시 유도체 작제물 및 그의 용도
|
US20200054741A1
(en)
|
2017-04-04 |
2020-02-20 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
KR20230074284A
(ko)
|
2017-04-06 |
2023-05-26 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
비스-링키지를 사용한 세포독성 약물의 접합
|
US20180296685A1
(en)
|
2017-04-13 |
2018-10-18 |
Tarveda Therapeutics, Inc. |
Targeted constructs and formulations thereof
|
WO2018191746A1
(en)
*
|
2017-04-14 |
2018-10-18 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
US20200071417A1
(en)
|
2017-04-19 |
2020-03-05 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
CA3064869A1
(en)
|
2017-05-26 |
2018-11-29 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
WO2018227018A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody conjugates of immune-modulatory compounds and uses thereof
|
WO2018227023A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody construct conjugates
|
AU2017419352B2
(en)
|
2017-06-23 |
2024-05-30 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
AU2018290880A1
(en)
|
2017-06-28 |
2020-01-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for Dectin-2 stimulation and cancer immunotherapy
|
US11925693B2
(en)
|
2017-07-27 |
2024-03-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Polymeric nanoparticles for enhanced cancer immunotherapy
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
EP3668548A2
(en)
|
2017-08-17 |
2020-06-24 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
US11713356B2
(en)
|
2017-10-13 |
2023-08-01 |
Ose Immunotherapeutics |
Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
US10722591B2
(en)
|
2017-11-14 |
2020-07-28 |
Dynavax Technologies Corporation |
Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
|
CA3084667A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
JP7386161B2
(ja)
|
2017-12-19 |
2023-11-24 |
ブレイズ バイオサイエンス, インコーポレイテッド |
腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
|
US11884723B2
(en)
|
2018-03-13 |
2024-01-30 |
Ose Immunotherapeutics |
Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
US20210154188A1
(en)
|
2018-04-02 |
2021-05-27 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
CN115192726A
(zh)
|
2018-04-03 |
2022-10-18 |
深圳大学 |
免疫激动剂靶向化合物的合成及其应用
|
US11485741B2
(en)
|
2018-04-24 |
2022-11-01 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (TLR7) agonists
|
CN112153988A
(zh)
|
2018-05-17 |
2020-12-29 |
博尔特生物治疗药物有限公司 |
免疫缀合物
|
TWI834673B
(zh)
|
2018-06-04 |
2024-03-11 |
美商杜夫特學院信託管理公司 |
經腫瘤微環境活化之藥物-結合子共軛物及與其相關之用途
|
CN114573699A
(zh)
|
2018-07-09 |
2022-06-03 |
启德医药科技(苏州)有限公司 |
滋养层细胞表面抗原2(trop2)特异性抗体
|
AU2019311102A1
(en)
|
2018-07-24 |
2021-02-25 |
Torque Therapeutics, Inc |
TLR7/8 agonists and liposome compositions
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
WO2020047187A1
(en)
*
|
2018-08-29 |
2020-03-05 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting egfr
|
WO2020051356A1
(en)
|
2018-09-07 |
2020-03-12 |
Birdie Biopharmaceuticals, Inc. |
Imidazoquinoline compounds and uses thereof
|
AU2019339344A1
(en)
|
2018-09-12 |
2021-03-18 |
Silverback Therapeutics, Inc. |
Compositions for the treatment of disease with immune stimulatory conjugates
|
KR20210081339A
(ko)
|
2018-09-12 |
2021-07-01 |
실버백 테라퓨틱스, 인크. |
치환된 벤즈아제핀 화합물, 접합체, 및 이의 용도
|
WO2020056194A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
US20220323596A1
(en)
|
2018-09-12 |
2022-10-13 |
Silverback Therapeutics, Inc. |
Antibody conjugates of toll-like receptor agonists
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
EP3873938A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody conjugates comprising sting agonists
|
KR20210098488A
(ko)
|
2018-11-30 |
2021-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
|
JP7514836B2
(ja)
|
2018-12-12 |
2024-07-11 |
ブリストル-マイヤーズ スクイブ カンパニー |
トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
|
WO2020139618A1
(en)
|
2018-12-26 |
2020-07-02 |
Birdie Biopharmaceuticals, Inc. |
Immune modulatory combinations and methods for treating cancers
|
CA3125533A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma Oncology Division A/S |
Conjugates of pattern recognition receptor agonists
|
US20220089768A1
(en)
|
2019-01-04 |
2022-03-24 |
Trio Pharmaceuticals, Inc. |
Multi-specific protein molecules and uses thereof
|
MX2021009644A
(es)
|
2019-02-12 |
2021-09-08 |
Ambrx Inc |
Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
|
WO2020190734A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting pd-l1
|
US20220152215A1
(en)
|
2019-03-15 |
2022-05-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting CEA
|
WO2020190690A1
(en)
|
2019-03-15 |
2020-09-24 |
Birdie Biopharmaceuticals, Inc. |
Immune modulatory compositions and methods for treating cancers
|
US20220226492A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting HER2
|
WO2020190762A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported tlr agonists
|
EP3937984A1
(en)
|
2019-03-15 |
2022-01-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
KR20220031995A
(ko)
|
2019-04-05 |
2022-03-15 |
드렌 바이오, 인크. |
항체 표적화된 식균작용을 통해 질환 유발 인자를 고갈시키는 방법
|
EP3980080A1
(en)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
Immunomodulator antibody drug conjugates and uses thereof
|
WO2020252294A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
CA3143156A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported aminobenzazepine compounds
|
CN114746420A
(zh)
|
2019-06-17 |
2022-07-12 |
苏特罗生物制药公司 |
用于癌症治疗和诊断的作为Toll样受体(TLR)7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物
|
BR112021025699A2
(pt)
|
2019-06-19 |
2022-03-03 |
Silverback Therapeutics Inc |
Anticorpos anti-mesotelina e imunoconjugados dos mesmos
|
US20210139477A1
(en)
|
2019-07-16 |
2021-05-13 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
BR112022001931A2
(pt)
|
2019-08-02 |
2022-06-21 |
Mersana Therapeutics Inc |
Derivados de bis-[n-((5-carbamoil)-1h-benzo[d]imidazol-2-il)-pirazol-5-carboxamida e compostos relacionados como agonistas de sting (estimulador de genes de interferon) para o tratamento de câncer
|
MX2022001719A
(es)
|
2019-08-15 |
2022-03-11 |
Silverback Therapeutics Inc |
Formulaciones de conjugados de benzazepina y usos de las mismas.
|
EP4025254A1
(en)
|
2019-09-03 |
2022-07-13 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
WO2021046347A1
(en)
|
2019-09-04 |
2021-03-11 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
JP2022548310A
(ja)
|
2019-09-23 |
2022-11-17 |
シートムエックス セラピューティクス,インコーポレイテッド |
抗cd47抗体、活性化可能抗cd47抗体、およびその使用方法
|
US20220347310A1
(en)
|
2019-09-30 |
2022-11-03 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
EP4037709A4
(en)
|
2019-09-30 |
2023-10-11 |
The Board of Trustees of the Leland Stanford Junior University |
KNOTTIN-IMMUNSTIMULANT CONJUGATES AND RELATED COMPOSITIONS AND METHODS
|
AU2020358726A1
(en)
|
2019-10-01 |
2022-04-07 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
US20210130473A1
(en)
|
2019-10-09 |
2021-05-06 |
Silverback Therapeutics, Inc. |
TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
|
US20230257393A1
(en)
|
2019-10-25 |
2023-08-17 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported thienoazepine compounds, and uses thereof
|
TW202128226A
(zh)
|
2019-10-25 |
2021-08-01 |
美商博特生物治療公司 |
噻吩并氮呯免疫結合物及其用途
|
EP4069683A1
(en)
|
2019-12-06 |
2022-10-12 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
US20230101266A1
(en)
|
2019-12-31 |
2023-03-30 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
|
CN115175917A
(zh)
|
2019-12-31 |
2022-10-11 |
启德医药科技(苏州)有限公司 |
药物缀合物及其应用
|
CN115175939A
(zh)
|
2020-01-21 |
2022-10-11 |
博尔特生物治疗药物有限公司 |
抗pd-l1抗体
|
BR112022014358A2
(pt)
|
2020-01-21 |
2022-09-13 |
Bolt Biotherapeutics Inc |
Anticorpos anti-pd-l1
|
US11179473B2
(en)
|
2020-02-21 |
2021-11-23 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
CA3169117A1
(en)
|
2020-02-25 |
2021-09-02 |
Bolt Biotherapeutics, Inc. |
Cancer treatment methods
|
WO2021202921A1
(en)
|
2020-04-01 |
2021-10-07 |
Altimmune Uk Limited |
Imidazoquinoline-type compounds and uses thereof
|
CA3176248A1
(en)
|
2020-04-10 |
2021-10-14 |
Seagen Inc. |
Charge variant linkers
|
IL297782A
(en)
|
2020-05-01 |
2022-12-01 |
Bolt Biotherapeutics Inc |
Anti-dectin-2 antibodies
|
JP2023524271A
(ja)
|
2020-05-08 |
2023-06-09 |
ボルト バイオセラピューティクス、インコーポレーテッド |
エラスターゼ-基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
|